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ApoptosisVasodilator-stimulated phosphoprotein (VASP) and Zyxin are interacting proteins involved in cellular adhesion
andmotility. PKA phosphorylates VASP at serine 157, regulating VASP cellular functions. VASP interactswith ABL
and is a substrate of the BCR–ABL oncoprotein. The presence of BCR–ABL protein drives oncogenesis in patients
with chronic myeloid leukemia (CML) due to a constitutive activation of tyrosine kinase activity. However, the
function of VASP and Zyxin in BCR–ABL pathway and the role of VASP in CML cells remain unknown. In vitro
experiments using K562 cells showed the involvement of VASP in BCR–ABL signaling. VASP and Zyxin inhibition
decreased the expression of anti-apoptotic proteins, BCL2 and BCL-XL. Imatinib induced an increase in phosphor-
ylation at Ser157 of VASP and decreased VASP and BCR–ABL interaction. VASP did not interactwith Zyxin inK562
cells; however, after Imatinib treatment, this interaction was restored. Corroborating our data, we demonstrated
the absence of phosphorylation at Ser157 in VASP in the bone marrow of CML patients, in contrast to healthy do-
nors. Phosphorylation of VASP on Ser157 was restored in Imatinib responsive patients though not in the resistant
patients. Therefore, we herein identiﬁed a possible role of VASP in CML pathogenesis, through the regulation of
BCR–ABL effector proteins or the absence of phosphorylation at Ser157 in VASP.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Chronic myeloid leukemia (CML) is a clonal myeloproliferative
neoplasm of the hematopoietic stem cell, characterized by the presence
of the fusion protein breakpoint cluster region-abelson (BCR–ABL), an
oncoprotein with a constitutively tyrosine kinase activity. Signiﬁcant
efforts are being made to understand the molecular mechanisms of
BCR–ABL signaling pathway [1]. Imatinib mesylate (Gleevec/Glivec,
STI571) is a speciﬁc BCR–ABL tyrosine kinase inhibitor that can lead
towards the elimination of the clone of BCR–ABL positive cells [2]; how-
ever there are patients that fail to respond to this treatment. Thus, the
combination of tyrosine kinase inhibitors and other targets has been
intensiﬁed in an attempt to induce apoptosis of resistant CML cells,
including the strategies targeting BCL-2 protein family [3–6]. The
cross-talk between the aberrant BCR–ABL signaling and BCL2 protein
family has been described and has generated new therapeutic opportu-
nities [7].therapy Center, University of
as, SP, Brazil. Tel.: +55 19 3521
os).Several mechanisms inﬂuence disease evolution leading to uncon-
trolled cell proliferation, resistance to apoptotic and altered migration
of CML cells. BCR–ABL oncoprotein induces multiple abnormalities of
cytoskeletal function, resulting in an increased mobility and a reduced
adhesion of leukemic cells to bone marrow stroma [8,9]. Dysregulation
of actin polymerization and the depolymerization process are often
associated with tumor development [10–12].
Cytoskeleton protein activity and the actin reorganization are essen-
tial to a variety of cellular processes including cell motility, cell division,
cellular differentiation, and establishment and maintenance of cell adhe-
sion [13,14]. VASP (vasodilator-stimulated phosphoprotein) and Zyxin
are two important actin regulatory proteins; that act as a protein complex
involved in driving actin dynamics in the context of cell division and the
formation and maintenance of cell junctions [15,16]. Zyxin directs actin
assembly by recruiting VASP to speciﬁc sites of adhesion [17,18].
VASP is a member of the Ena/VASP protein family. These family
members share a conserved structure consisting of an N-terminal
homology EVH1 domain, a central poly-proline region (PPR) and a
C-terminal EVH2 domain [19]. The C-terminal of Zyxin has an
N-terminal proline-rich domain and three LIM domains. The proline-
rich domain may interact with SH3 domains of proteins involved in
signal transduction pathways while the LIM domains are probably in-
volved in protein-protein binding [19]. VASP interacts with Zyxin
through the proline-rich region or through the LIM domain, though
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phorylation state [20]. VASP is a substrate of cAMP-dependent and
cGMP-dependent protein kinase and phosphorylation at Ser157 in
VASP regulates its interaction with actin [21]. In addition, Zyxin phos-
phorylation has been proposed to modulate its head–tail interaction to
alter protein binding and thus cell–cell adhesion [16,22].
Altered expression of VASP and its partner Zyxinhas been previously
described in a variety of epithelial tumors [23–26]; however little is
known regarding their involvement in hematopoietic tumors, particu-
larly CML. VASP homologues in Drosophila were identiﬁed as substrates
of the tyrosine kinase ABL [27]. In mammals, the physical interaction of
VASPwithABL and its tyrosine phosphorylationwere both demonstrated
[28]. However, the connection of VASP and Zyxin to BCR–ABL signaling
pathway in the context of CML remains unclear. In addition, the phos-
phorylation of VASP on Ser157 in CML leukemic cells and how this phos-
phorylation is affected by Imatinib treatment are not yet known. Herein
we described VASP and Zyxin interaction in K562 cells before and
after Imatinib treatment and phosphorylation of VASP on Ser157 status
in K562 cells and in CML patient bone marrow cells. We characterized
VASP and Zyxin participation and action in downstream effectors of
BCR–ABL signaling.2. Materials and methods
2.1. Bone marrow samples
Bone marrow samples were collected from 5 individuals: 1 healthy
donor, 1 patient with a diagnosis of chronic myelogenous leukemia
(CML), 1 responsive patient in major molecular remission treated with
tyrosine kinase inhibitors and 2 patients resistant to treatment. Samples
were collected between 2011 and 2012 after informed written consent
and the study was approved by the Ethics Committee of the University
of Campinas. Total cells from bonemarrow samples were obtained after
removing erythrocytes by hemolysis.2.2. Cell culture and reagent chemicals
K562 cells, which are known as a representative human CML cell
line, were obtained from ATCC, Philadelphia, PA, USA. Cells were cul-
tured in RPMI containing 10% fetal bovine serum (FBS) and glutamine
with penicillin/streptomycin and amphotericin B, and maintained at
37 °C, 5% CO2. Imatinib mesylate was kindly provided by Novartis
Pharmaceuticals (Basel, Switzerland) and prepared as a 50 mM stock
solution in dimethyl sulfoxide (Me2SO4; DMSO) and used at ﬁnal con-
centrations of 0.1, 0.5 or 1 μM, as indicated.2.3. Lentiviral vectors
K562 cells were transduced with lentivirus-mediated shRNA nonspe-
ciﬁc control (sc-108080) or lentivirus-mediated shRNA targeting VASP
(shVASP; sc-29516-V) and Zyxin (shZyxin; sc-36370-V) from Santa
Cruz Biotechnology (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Brieﬂy, 2 × 105 cells were transduced with lentiviral by spinoculation
at multiplicity of infection equal to 3 and selected by puromycin
(1.75 μg/mL).2.4. RNA extraction and Reverse Transcription
Total RNA was extracted using the Trizol® reagent (Invitrogen)
according to the manufacturer's instructions. Single stranded cDNA was
synthesized from 2 μg of the total RNA preparation using SuperScript®
III Reverse Transcriptase kit (Invitrogen Life Technologies).2.5. Quantitative polymerase chain reaction
Quantitative PCR (qPCR) was performed using ABI 7500 Sequence
Detector System (Applied Biosystems, Foster City, CA, USA) with speciﬁc
primers for VASP, Zyxin and HPRT. Primer sequences and concentrations
are described in Supplementary Table 1. The relative gene expression
was calculated using the equation, 2−ΔΔCT [29].
2.6. Immunoblotting
Pelleted cells were resuspended in RIPA buffer, incubated for 45min
at 4 °C and centrifuged for 30 min at 12,000 rpm at 4 °C. The same
amount of protein was loaded on SDS-PAGE and blots were probed
with the indicated antibodies and ECL Western Blot Analysis System
(Amersham Pharmacia Biotech, UK). Antibodies against ABL (sc-23),
p-ERK (sc-7383), P70S6K (sc-8418), CRKL (sc-319), BAX (sc-20067),
Actin (sc-1616), p-P70S6K (sc-7984), BCL-XL (sc-8392), BCL2 (sc-492),
p-BAD (sc-7999), BAD (sc-943), p-STAT 5 (C11C5), STAT 5 (sc-835),
FAK (sc-558), BAK (sc-G23) and VASP (sc-1853) were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Antibodies against p-CRKL (3181),
p-p130 CAS (4011), p130 CAS (12015), p-VASP (3111), and BIM (2819)
were from Cell Signaling Technology (Cell Signaling, Danvers, MA, USA)
and Anti-ERK1/2 (13-6200) was from Zymed (Invitrogen, Carlsbad, CA,
USA). Antibodies against p-JNK (44690G) and JNK (446826) were from
Invitrogen and antibody against p-FAK Y397 (ab4803), p-FAK Y576/577
(ab76244), p-FAK Y861 (ab38458), p-FAK Y925 (ab38512), p-Zyxin
(ab78910) and Zyxin (ab58210) was from Abcam (Cambridge, MA,
USA). The membranes were stripped and reprobed with antibodies for
detection of the respective total proteins and of Actin as control of
loading.
2.7. Immunoprecipitation
K562 cell lysates were prepared in RIPA buffer containing protease
inhibitors, as previously described [30]. Brieﬂy, 500 μg of total K562
cell extracts was incubated overnight with 20 μL anti-VASP antibody
(Santa Cruz Biotechnology) or with normal goat immunoglobulin
(IgG) as a negative control. The immune complexes were precipitated
with protein-G-sepharose 50% slurry (GE), washed in RIPA buffer to re-
move unspeciﬁc proteins, and then analyzed by western-blotting with
the antibodies of interest.
2.8. Confocal immunoﬂuorescence microscopy
Confocal imaging was carried out using primary antibodies against
VASP or Zyxin (diluted 1:200), as previously described [31]. Actin was
stained by Phalloidin (1:1000; Invitrogen). Imaging was performed
using a Zeiss LSM780-NLO confocal on anAxio Observer Z.1microscope
(Carl Zeiss AG, Germany) with a 63× optical zoom.
2.9. Methylthiazoletetrazolium (MTT) assay
Cell proliferation/viability wasmeasured byMTT assay as previously
described [32]. Cells were serum-starved in 0.5% FBS for 12 h. A total
of 5 × 104 cells per well were then plated in a 96-well plate in RPMI
10% FBS. In brief, 10 μL of a 5 mg/mL solution of MTT was added to the
wells and incubated at 37 °C for 4 h. The reaction was stopped by
using 100 μL of 0.1 N HCl in anhydrous isopropanol. Cell proliferation/
viability was evaluated by measuring the absorbance at 570 nm,
using an automated plate reader. All conditions were tested in six
replicates.
2.10. Colony formation assay
Colony formation was carried out in semisolid methyl cellulose
medium. 1 × 103 cell/mL was seeded in MethoCult 4230 (StemCell
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after 8 days of culture by adding 1 mg/mL of MTT reagent and scored
by Image J quantiﬁcation software (U.S. National Institutes of
Health).Fig. 1. VASP and Zyxin modulate apoptosis-related proteins. (A–D) Evaluation of VASP and Zyxi
mediated shRNA targeting VASP and Zyxin by quantitative RT-PCR analysis (A, C) andWestern blo
of protein expression and activity. Respective total protein or Actin was used as a control to ensu2.11. Apoptosis assays
Cellswerewashed twicewith ice cold PBS and resuspended in binding
buffer containing 1 μg/mL PI and 1 μg/mL APC labeled Annexin-V.n silencing in K562 cells transduced with lentivirus-mediated shRNA control and lentivirus
tting analysis (B, D), respectively. (E–G)Western blotting analysiswas used for quantiﬁcation
ring equal sample loading; the antibodies used for immunoblotting (IB) are indicated.
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15minutes at room temperature in a light-protected area. Ten thousand
events were acquired for each sample.
2.12. Statistical analysis
Statistical analyses were performed using GraphPad Instat 5
(GraphPad Software, Inc., San. Diego, CA, USA). For comparisons, an
appropriate Student's t-test or analysis two-way ANOVA test and
Bonferroni post-test were used. P-value b0.05 was considered as statis-
tically signiﬁcant.
3. Results
3.1. VASP participates in BCR–ABL pathway modulating effector proteins as
BCL2, BCL-XL and FAK activity
In an attempt to understand the cellular effects of the interaction
between VASP and BCR–ABL, we silenced VASP and Zyxin in K562 cells
and analyzed the activity effector proteins in the BCR–ABL signalingFig. 2.Knockdownof VASP andZyxin increases Imatinib-induced apoptosis. (A) and (C) Apoptos
treated or treatedwith imatinib (0.1, 0.5 and 1 μM for 48 h) using Annexin-V and PI stainingm
population. (B) and (D) Dot plots are representative of one experiments and bars graphs indica
the ﬁgure; two-way ANOVA test and Bonferroni post-test. Western blotting analysis of total e
protein expression and activity. Respective total protein or Actin was used as a control to ensupathway. The analysis showed a signiﬁcant reduction by qPCR, 60% for
VASP and 75% for Zyxin (Fig. 1A, 1C), as well as by western blot (81%
for VASP and 99% for Zyxin) (Fig. 1B, 1D).
The silencing of VASP and Zyxin in BCR–ABL positive cells allowed us
to analyze their effects upon functional studies. Brieﬂy, we divided
BCR–ABL pathway effectors into three categories: those involved in
apoptosis (BCL2, BCL-XL, BAD, BAX and BAK), proliferation (JNK1/2,
ERK1/2, STAT5 and P70S6K), and adhesion (CRKL, p130 CAS and
FAK). The expression of anti-apoptotic proteins BCL2 and BCL-XL
was reduced in VASP and Zyxin K562 depleted cells (Fig. 1E). How-
ever, there was no change in the phosphorylation or expression of
pro-apoptotic proteins BAD, BAX and BAK in K562 depleted of
VASP or Zyxin as compared to control cells (Fig. 1E). The activity of
proliferation-related proteins was not modulated by VASP and Zyxin
silencing (Fig. 1F).
Concerning adhesion proteins, VASP depletion resulted in a signiﬁcant
reduction in phosphorylated FAK at Tyr925, whereas Zyxin depletion did
not affect activation of FAK (Fig. 1G). Activity of adhesion related proteins
p130CAS and CRKL was similar in controls and VASP- or Zyxin-silenced
cells.iswas detected byﬂow cytometry in shControl, shVASP and shZyxin cells, respectively, not
ethod. The lower right quadrant indicates the percentage of apoptotic (Annexin-V+/PI−)
te themean± SD of at least three independent experiments. The P values are indicated in
xtracts from shControl and shVASP (E) or shZyxin (F) cells was used for quantiﬁcation of
ring equal sample loading; the antibodies used for immunoblotting (IB) are indicated.
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Imatinib treatment
To evaluate the effect of VASP and Zyxin on apoptosis, cell growth and
clonogenicity, K562 cells depleted of either VASP or Zyxin, aswell as con-
trol cells, were treated with 0.1, 0.5 or 1 μM Imatinib and the dose–re-
sponse effect of the drug was observed. VASP- and Zyxin-silenced cells
had higher rates of apoptosis when treated with 1 μM Imatinib as
compared to control cells (P b 0.05; Fig. 2A–D). These ﬁndings were in
agreement with our data that suggested a higher sensibility to apoptosis,
as observed by downregulation of anti-apoptotic proteins BCL2 and
BCL-XL in VASP- and Zyxin-depleted cells. Of note, Imatinib treatment
impacted on the BCL2 and BCL-XL expression, and the lowest levels
were observed in VASP- and Zyxin-depleted cells treated with 1 μM of
Imatinib (Fig. 2E–F). BIM expression was not modulated by VASP or
Zyxin depletion (Fig. 2E–F).
The role of VASP and Zyxin in cell growth/viability was analyzed
in an MTT assay. There was no difference in cell growth in VASP-
depleted cells (Fig. 3A). However, Zyxin-depleted cells treated with
0.5 and 1 μMof Imatinib showed a signiﬁcant reduction in cell viabil-
ity (P b 0.01; Fig. 3B), which may be a consequence of the increased
apoptosis. There were no signiﬁcant changes in the number of colo-
nies in shVASP and shZyxin cells compared to shControl cells (Fig. 3C
and D).
3.3. Imatinib treatment restores VASP and Zyxin interaction in CMLK562 cells
CML progression is characterized by altered adhesion and increased
mobility of premature leukemic cells released from the bone marrow
and this process could compromise the association between the cyto-
skeletal and adhesion proteins of the extracellularmatrix [8,10]. The in-
teraction of VASP and Zyxin is well characterized in epithelial tissue;Fig. 3. VASP and Zyxin silencing does not modulate proliferation and clonogenicity. (A) and (
shVASP or shZyxin K562 cells, respectively, treated or not with imatinib mesylate (0.1; 0.5 or 1
centage, and normalized to the shControl value set as 100%. Results are shown as mean± SD of
ANOVA test and Bonferroni post-test (C) and (D) shControl or shVASP or shZyxin cells were cult
orwithout treated imatinibmesylate (0.1; 0.5 or 1 μM) andwerenormalized by untreated shCo
100%. Colony images are representative of one experiment and the bar graphs are shown as mhowever their interaction in CML is unknown. By immunoprecipitated
and western blotting, we demonstrated that VASP and Zyxin do not in-
teract in K562 cells; however, after treatment with Imatinib (1 μM),
VASP and Zyxin interacted, indicating that the association of VASP and
Zyxin is impaired by BCR–ABL activity (Fig. 4A). Confocal analysis did
not reveal differences in Actin remodeling in cells treated with Imatinib
(1 μM) for 12 h compared to control cells. However, analyses performed
here are limited by the compact cytoplasm in this cell line (Supplemen-
tary Fig. 1).3.4. Imatinib treatment increases VASP phosphorylation on Ser157 and
reduces VASP interaction with BCR–ABL
Serine 157 is an important site of phosphorylation on VASP that
regulates adhesive functions and its interactions with other proteins
[21]. Here we attempted to analyze phosphorylation at Ser-157 in
VASP of BCR–ABL positive cells and Imatinib effect on this phosphoryla-
tion. K562 cells were treated with Imatinib (1 μM) for 3, 6, 9 and 12 h
and an increase in phosphorylation at ser157 of VASP was observed
after 3 hours of treatment (Fig. 4B).
Since VASP interacts with ABL and VASP is tyrosine phosphorylated
by BCR–ABL [28], we sought to study the interaction of VASP and
BCR–ABL in K562 cells and the effect of Imatinib on this interaction.
Imatinib treatment was performed as previously described by our
group [33]. Lysates of K562 cells treated with 1 μM Imatinib for 3, 6, 9
and 12 h, as well as untreated controls, were subjected to immunopre-
cipitation with anti-VASP antibodies. Western blotting demonstrated
the interaction between VASP and BCR–ABL; this interaction was re-
duced during Imatinib treatment (Fig. 4C). Taken together these results
suggest that phosphorylation of VASP at serine 157 or BCR–ABL activity
may modulate the association between these proteins.B) Cell proliferation/viability was determined by MTT assay of incubation of shControl or
μM) after 48 h and normalized by untreated shControl cells. Values are expressed in per-
at least three independent experiments. The P values are indicated in the ﬁgure; two-way
ured inmethyl cellulose and colonieswere detected byMTT after 8 days of incubationwith
ntrol cells. Values are expressed in percentage, and normalized to the shControl value set as
ean ± SD of at least three independent experiments.
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Since altered actin dynamics may be involved in tumorigenesis and
VASP interaction with actin is regulated by phosphorylation in ser157,
we investigated phosphorylation at Ser157 in VASP status in bone
marrow cells from 1 healthy donor control and 4 CML patients (1 at di-
agnosis, 1 in molecular remission and 2 Imatinib resistant patients).
Healthy donor cells showed phosphorylation at serine 157 of VASP, in
contrast to CML cells which did not express phosphorylation at Ser157
in VASP. After Imatinib treatment, VASP phosphorylation at ser157
was restored in CML bonemarrow cells; however thiswas not observed
in Imatinib resistant patients (Fig. 4D).
4. Discussion
ABL protein plays a key role regulating many cellular processes,
including cytoskeletal function and adhesion [34]. The constitutively ac-
tive BCR–ABL fusion protein is observed in CML, where it inﬂuences theFig. 4. Imatinib treatment enhances VASP and Zyxin interaction, increases VASP phosphorylatio
K562 cells untreated and treated with Imatinib (1 μM) were immunoprecipitated (IP) with ant
protein extract (input) and isotype IgG antibodywere used as controls.(B)Western-blotting usi
(1 μM) for 3, 6, 9 and 12 h. (C) Endogenous VASP were co-immunoprecipitated with BCR–ABL
precipitation with an anti-VASP antibody followed by western blot analysis using anti-ABL and
controls. (D)Western blotting showed phospho-VASP ser 157, VASP, phospho-Zyxin ser 142 an
two resistant to Imatinib. Actin staining indicates the amount of protein loaded. All images in F
with different antibodies. Actin was used as a control to ensuring equal sample loading; the ancytoskeleton and affects adhesion of CML cells to bone marrow stroma
[35]. The connection between the oncogenic activity of BCR–ABL and
its role in CML is unclear. Herewe studied the role of VASP and its partner
Zyxin in CML cells and in BCR–ABL pathway.
We studied the phosphorylation at Ser-157 in VASP in CML bone
marrow cells and in K562 cells, a critical phosphorylation site for VASP
activity regulation. PKA phosphorylation is known to disrupt the
VASP–ABL interaction, blocking VASP binding to the SH3 domain of
ABL [21,36]. Inhibition of PKA activity prevents VASP phosphorylation
on serine 157 and promotes the association of VASP–ABL [37]. Those
ﬁndings suggest that the absence of phosphorylation at Ser157 in
VASP in CML patients and in K562 cellsmay promote the interaction be-
tween VASP and BCR–ABL in leukemic cells.
We demonstrated here that there is no phosphorylation of VASP at
ser157 in CML bone marrow cells. After Imatinib treatment, remission
patients restored phosphorylation of VASP on Ser157 expression and
CML patients resistant to Imatinib did not present phosphorylation at
Ser157 in VASP in their bone marrow cells. Consistent with thisn at serine 157 and reduces association of VASP and BCR–ABL. (A) The same lysates from
i-Zyxin antibody and immunoblotted (IB) with anti-Zyxin and anti-VASP antibodies. Total
ng anti-p-VASP ser157, anti-VASP and Actin antibodies in K562 cells treatedwith Imatinib
. Total extracts from K562 cells treated with Imatinib (1 μM) were submitted to immuno-
anti-VASP antibody. Total protein extract (input) and isotype IgG antibody were used as
d Zyxin in K562 cells, one healthy donor, one CML patient at diagnosis, one responding and
ig. 4E belong to the same western blotting and the membrane was stripped and reprobed
tibodies used for immunoblotting (IB) are indicated.
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status in K562 cells treated with Imatinib, strengthening the idea of
phosphorylation at Ser157 in VASP role in CML pathogenesis and in
Imatinib treatment.
In Drosophila, Abl regulates subcellular localization of Ena and in the
absence of Abl, Ena localizes to ectopic sites [38]. Abl may prevent Ena
from binding to partners that localize at cortical sites or may promote
Ena binding to proteins that maintain Ena in the cytoplasm [38]. In
addition, VASP phosphorylated on Ser157 localizes at focal adhesions
and PKA stimulation relocates VASP to focal adhesion [19,39]. PKA is a
known target of kinase inhibitors [40]; accordingly ourﬁndings indicated
that Imatinib, a kinase inhibitor, increased phosphorylation at Ser157 in
VASP and disrupted VASP–ABL interaction in BCR–ABL cells. Thus VASP
interacted with Zyxin. In CML disease progression, cancerous inﬁltration
of liver, kidney and spleen occurs as a consequence of altered CML cell ad-
hesion to bonemarrow stromal cells [28]; the absence of VASP and Zyxin
interaction, a key regulator complex of cell–cell adhesion,may contribute
to CML defective adhesion.
We demonstrated that VASP affects FAK phosphorylation, pointing
towards a possible role for VASP in controlling the migration and adhe-
sion of leukemic cells in CML patients through FAK activity also. In addi-
tion, FAKhas been shown to play a role as an anti-apoptotic protein [41].
Previous studies have shown that the reduction of BCL-2 or BCL-XL, or
overexpression of proapoptotic protein (e.g. BIM, BAD) contributes to
the better Imatinib response of K562 cells [3,42,43]. Therefore, compo-
nents that mimic BH3-only protein, which inhibits the anti-apoptotic
function of some members of the BCL2 family, are being used in an
attempt to overcome resistance to tyrosine kinase inhibitors [3–6]. Our
ﬁndings that VASP depletion affected the expression of anti-apoptotic
proteins are consistent with this idea.
Herein we pointed towards a possible involvement of the absent
phosphorylation of VASP at ser157 in CML cells and the lack of VASP
and Zyxin interaction in K562 cells into the defective cellular adhesion
of CML cells to stromal cells, which implicates inmigration and invasion
of leukemic cells. Our results suggest a crucial participation of VASP on
Imatinib treatment, where phosphorylation at Ser157 in VASP disasso-
ciates from ABL and VASP interacts to Zyxin. Future studies targeting
VASP and Zyxin in primary CML cells may provide more information
about the function of these proteins in the CML phenotype.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.11.008.
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